Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

PeptiDream cuts half-year loss and confirms full-year guidance, pipeline expands

PeptiDream reported H1 2026 revenue of JPY 9.2 billion, an operating loss of JPY 2.5 billion and EPS of -15.51 JPY. Management confirmed the full-year revenue target of JPY 32 billion and expects a return to profitability in fiscal year 2026. The clinical pipeline grew from 13 to 19 programs, and PDRadiopharma increased PET product sales by 30%. The stock reacted moderately positively, last trading at $1,007 (+1.49%). » Mere på de.investing.com
PeptiDream announces quarterly results for 31 December 2025, analysts see smaller loss and revenue growth

PeptiDream will publish results for the quarter ended 31 December 2025 on 16 February 2026. On average, 3 analysts expect a quarterly loss per share of -5.695 JPY versus -20.100 JPY a year earlier. Four analysts forecast revenue to rise 18.27% to around 6.00 billion JPY. For the past fiscal year, consensus expectations (8 analysts) are for a loss per share of -10.743 JPY and annual revenue averaging 18.63 billion JPY. » Mere på finanzen.net
PeptiDream expects smaller EPS loss and revenue rise in last quarter

PeptiDream will publish results for the quarter ended December 31, 2025 on February 16, 2026. Three analysts on average expect an EPS loss of −5,695 JPY per share (previous year −20,100 JPY). Revenue is estimated by four analysts at an average of 6.00 billion JPY, an increase of 18.27% from 5.07 billion JPY in the year-ago quarter. For the fiscal year, eight analysts on average see a loss per share of −10,743 JPY and revenue of 18.63 billion JPY. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2011 har PEPTIDREAM INC. allerede udloddet 0,17 € i udbytte. Den seneste udlodning fandt sted i august 2011.

Virksomhedstal

I det seneste kvartal havde PEPTIDREAM INC. en omsætning på 24,04 mio. € og et nettoresultat på -6,17 mio. €

(EUR)	juni 2026	YoY
Omsætning	24,04 mio.	5,47 %
Bruttofortjeneste	10,45 mio.	4,41 %
Nettoresultat	-6,17 mio.	4,04 %
EBITDA	-4,98 mio.	14,69 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	767,19 mio. €
Antal aktier	128,49 mio.
Højeste/laveste i 52 uger	10,06 € - 5,09 €
Udbytte	Nej
Beta	0,35
P/E (PE Ratio)	-37,85
PEG (PEG Ratio)	-2,17
K/I (PB Ratio)	2,82
P/S (PS Ratio)	7,12

Virksomhedsprofil

PeptiDream Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von gebundenen Peptiden, kleinen Molekülen und Peptid-Wirkstoff-Konjugaten beschäftigt. Das Unternehmen entwickelt seine Produkte auf der Grundlage seines Peptide Discovery Platform System, einer Wirkstofffindungsplattform für die Entwicklung von Peptiden. Es hat eine Forschungskooperation und eine exklusive Lizenzvereinbarung mit Takeda Pharmaceutical Company Limited zur Entwicklung von Peptid-Wirkstoff-Konjugaten für neuromuskuläre Krankheiten. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Kawasaki, Japan.